ImmunoGen Inc. (IMGN)

HEALTH CARE: PHARMACEUTICALS
SIC: PHARMACEUTICAL PREPARATIONS

830 WINTER ST WALTHAM, MA 02451

ImmunoGen Inc. discovers and develops therapeutic monoclonal antibodies and novel treatments in the field of oncology. Its lead technology, which it refers to as tumor-activated prodrug, uses antibodies to deliver potent cell-killing agents specifically to cancer cells.

Data as of 2020-05-30
Market Cap816.22 Million Shares Outstanding174.406 Million Avg 30-day Volume2.633 Million
P/E Ratio Dividend Yield EPS-0.57
Price/Sales9.385 Price cash flow ratio141.0 Price free cash flow ratio-6.6
Book Value-0.02 Price to Tangible Book-204.03 Alpha0.0
Short Interest Ratio % Short Interest to Float R-squared0.164795
BETA2.30851 52-week High/Low7.07 / 1.76 Stddev0.242697
View SEC Filings from IMGN instead.

View recent insider trading info

Funds Holding IMGN (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding IMGN BETA

Active Schedule 13D and 13G filings

Please sign in first

Open Market Buys/Sells Last 60 Days

Open Market Buys (P)

none

Open Market Sells (S)

none

Exercise Derivative Conversion (M)

none

Current/Former Insiders

Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

JUNIUS DANIEL M

  • Director
0 2020-05-22 0

GOLDBERG MARK ALAN

  • Director
0 2020-05-22 5

POOLE SANDRA

  • Director
6,500 2020-05-15 0

ARBUCKLE STUART A EVP, CHIEF COMMERCIAL OFFICER

  • Officer
35,319 2020-05-15 1

PIEN HOWARD H

  • Director
0 2020-05-12 0

MITCHELL DEAN J

  • Director
41,206 2020-04-28 5

FOSTER DAVID G V.P.-FIN., PRIN. ACCTG. OFF.

  • Officer
21,382 2020-04-01 5

ENYEDY MARK J

  • Director
0 2020-03-17 3

PETERSON KRISTINE

0 2020-02-28 1

MORRIS CHARLES Q CHIEF MEDICAL OFFICER

  • Officer
33,744 2020-02-26 0

BARROWS CRAIG EXECUTIVE VP, GENERAL COUNSEL

  • Officer
145,275 2020-02-24 2

WINGROVE THERESA SVP OF REGULATORY AFFAIRS

  • Officer
70,498 2020-02-24 3

BERKENBLIT ANNA SVP & CHIEF MEDICAL OFFICER

  • Officer
98,089 2020-02-24 3

RYLL THOMAS SVP, TECHNICAL OPERATIONS

  • Officer
75,624 2020-02-24 4

MCKEE BLAINE H.

  • Director
0 2020-01-22 1

PERRY GREGORY D

  • Director
0 2020-01-01 0

GREGORY RICHARD J.

  • Director
10,806 2019-11-18 0

ONETTO NICOLE

  • Director
0 2019-09-30 0

MCCLUSKI STEPHEN C

  • Director
13,507 2019-08-13 1

WALLACE RICHARD JOHN

  • Director
0 2019-06-20 1

SAYARE MITCHEL

  • Director
0 2019-01-02 0

JOHNSTON DAVID BRANNON CHIEF FINANCIAL OFFICER

  • Officer
180,690 2018-06-06 0

VILLAFRANCA JOSEPH J

  • Director
0 2017-12-31 0

WILLIAMS PETER J. VP, BUSINESS DEVELOPMENT

  • Officer
50,620 2017-02-23 0

LAMBERT JOHN EXECUTIVE VICE PRESIDENT

  • Officer
120,521 2016-11-02 0

HARRISON ELLIE VP & CHIEF HR OFFICER

  • Officer
0 2016-07-18 0

O'LEARY JAMES J VICE PRESIDENT

  • Officer
0 2014-07-17 0

SKALETSKY MARK B

  • Director
No longer subject to file 2013-11-13 0

CARTER DAVID WARREN

  • Director
0 2012-07-02 0

CADDEN SUZANNE SVP, DEVELOPMENT

  • Officer
0 2011-09-14 0

SAMANA CAPITAL, L.P.

MORTON HOLDINGS, INC.

KORSANT PHILIP B

  • 10% Owner
No longer subject to file 2009-07-31 0

ZIFF ASSET MANAGEMENT LP

PBK HOLDINGS INC

KORSANT PHILIP B

ZBI EQUITIES, L.L.C.

  • 10% Owner
9,046,200 2008-06-20 0

TAGLIAMONTE JOHN VP, BUSINESS DEVELOPMENT

  • Officer
0 2008-06-11 0

Insider Transactions Last 60 Days

Reporting Owners Transaction Date Transaction Code Shares Share Price Acquired or Disposed Shares Owned Following Transaction Combined shares owned after filing Direct/Indirect Ownership 10b-5
No current insider transactions

Elevate your investments